Healthcare Industry News: blood glucose monitoring
News Release - August 22, 2007
GlucoLight Successfully Completes First Hypoglycemic ''Clamping'' Study of Sentris-100(TM)BETHLEHEM, Pa.--(HSMN NewsFeed)--GlucoLight Corporation, a development-stage company focused on blood glucose monitoring in the acute care environment, today announced the successful conclusion of the company's first hypoglycemic "clamping" study to evaluate its continuous, non-invasive glucose monitor, Sentris-100(TM).
The study yielded a number of important results regarding the performance of Sentris-100. Using a first generation "multi-spot sensor," GlucoLight demonstrated its strongest correlation to date between blood glucose levels and the Sentris-100 optical measurement. Furthermore, the study produced statistical evidence that Sentris-100 can measure glucose levels effectively between 50 and 400 mg/dl.
Utilizing ten volunteers with Type 1 diabetes mellitus, researchers stabilized blood glucose levels at a "normal" level of 100-130 mg/dl. Then, using a slow intravenous infusion of insulin, the volunteers' glucose levels were taken down to hypoglycemic levels of about 50 mg/dl for approximately 30 minutes, before being returned to normal levels. Sentris-100 was used to continuously monitor blood glucose levels during the test period, and checked against more traditional testing methods. The study was conducted at dgd Research in San Antonio, TX.
"The results of our hypoglycemia clinical study have been positive and show that we continue in the right direction," said Ray Krauss, Chief Executive Officer of GlucoLight Corporation. "The primary objective of this study was to monitor low blood sugar in subjects with Type 1 diabetes, and show an accurate correlation to clinical chemistry testing methods. We're also pleased with the performance of our first generation multi-spot sensor and its ability to effectively monitor blood glucose levels in the dermis."
GlucoLight will now focus on further refinements to Sentris-100 based on the new clinical data. In addition, the Company plans to reduce the size of its current multi-spot sensor and cable by 75%. The next clinical study is currently slated for the fourth quarter of 2007, with a second ICU clinical study in early 2008. GlucoLight is targeting the first introduction of the Sentris-100 in the ICU, where tight glycemic control has been shown to significantly improve survival, yet current monitoring provides only intermittent information.
The GlucoLight Sentris-100 monitor requires regulatory clearance and is not yet commercially available.
About GlucoLight Corporation
Formed in 2003, GlucoLight is a development-stage company focused on continuous, non-invasive blood glucose monitoring in the acute care environment.
Using Optical Coherence Tomography (OCT), GlucoLight has identified specific physiological targets within the dermis that closely correlate to changes in blood glucose levels. GlucoLight's Sentris-100(TM) monitor samples these physiological targets once per minute to track blood glucose levels to a high degree of accuracy.
Today, GlucoLight's Sentris-100(TM) monitor is the only continuous, non-invasive blood glucose monitor for the acute care environment that is in clinical trials.
For more information, visit www.GlucoLight.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.